Bernd R Anger

Title: Bernd R Anger: Innovator in Cancer Research

Introduction

Bernd R Anger is a notable inventor based in Kreiensen, Germany. He has made significant contributions to the field of cancer research, particularly through his work on monoclonal antibodies. With a total of two patents to his name, Anger's innovations are aimed at improving the diagnosis and treatment of lung cancers.

Latest Patents

Anger's latest patents include groundbreaking work on monoclonal antibodies to human lung cancers. This patent describes a panel of monoclonal antibodies produced from normal human lung fibroblasts and human lung tumors, which are used to diagnose the presence of lung tumors. It also differentiates between benign tumors and those that are cancerous. Another significant patent focuses on monoclonal antibodies for the detection of an H (O) blood group antigen. This patent discloses monoclonal antibodies that recognize the difucosyl-type-2-H antigen on human cells, providing valuable tools for blood typing and diagnosing blood disorders and malignancies.

Career Highlights

Bernd R Anger is affiliated with the Sloan-Kettering Institute for Cancer Research, where he continues to advance his research in cancer diagnostics. His work has been instrumental in developing methods that enhance the understanding and treatment of lung cancer.

Collaborations

Anger has collaborated with esteemed colleagues such as Kenneth O Lloyd and Herbert F Oettgen, contributing to a rich environment of innovation and research in cancer treatment.

Conclusion

Bernd R Anger stands out as a significant figure in the realm of cancer research, with his patents paving the way for advancements in diagnosis and treatment. His contributions are vital in the ongoing battle against cancer, showcasing the importance of innovation in medical science.